CPC A61K 31/7036 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0078 (2013.01); A61K 9/127 (2013.01); A61K 31/133 (2013.01); A61K 31/407 (2013.01); A61K 31/4375 (2013.01); A61K 31/4409 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/5383 (2013.01); A61K 31/546 (2013.01); A61K 31/65 (2013.01); A61K 31/7048 (2013.01); A61K 31/7052 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01)] | 27 Claims |
1. A method for treating a non-cystic fibrosis (CF) Mycobacterium avium complex (MAC) lung infection in a patient in need thereof, comprising:
administering to the lungs of the patient a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, encapsulated in a plurality of liposomes, wherein the lipid component of the plurality of liposomes consists of an electrically neutral phospholipid and cholesterol,
wherein administering to the lungs of the patient comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient once daily in a single dosing session, for an administration period of at least 84 days,
administering to the patient during the administration period one or more additional therapeutic agents selected from the group consisting of a macrolide antibiotic, a rifamycin, and ethambutol, and
wherein the treating comprises achieving a negative MAC sputum culture in the patient during the administration period or subsequent to the administration period.
|